Seattle Children's inaugurates new center for cancer research

Today, Seattle Children's Research Institute announced the opening of the Center for Childhood Cancer Research. In tandem, Michael Jensen, MD was named as the Center's director. The focus of the Center for Childhood Cancer Research will be to develop innovative new therapies in its laboratories and translate these advances to groundbreaking clinical trials for children with the most aggressive forms of cancer. The new center's long-term mission is to eventually replace cancer therapies such as radiation and chemotherapy that can harm the body, with new, "smart" therapies capable of eliminating cancer with precision, leaving the body unharmed.

Dr. Jensen and his team will focus their work on harnessing the therapeutic potential of the immune system. Specifically, they will work to reprogram the body's infection-fighting T-cells to seek out and destroy cancer cells wherever they are hiding in the body.

Steps of T-cell therapy include:
•T-Cell Isolation: Healthy T-cells are collected in a tube of blood and taken to the Center for Childhood Cancer Research biofactory. There, the patient's T-cells will be isolated and prepared for reprogramming.
•Genetic Reprogramming: T-cells are genetically reprogrammed with designer DNA that codes for artificial receptors which enable them to find and destroy cancer cells.
•T-cell Duplication: Reprogrammed T-cells are then duplicated into several billion T-cells outside the body.
•Transferring: Genetically reprogrammed T-cells are then transfused back to the child with cancer where they are expected to hunt down and eliminate cancer cells.

The Center for Childhood Cancer Research's Therapeutic Cell Production Core, a GMP (good manufacturing practices) biofactory, will facilitate the acceleration of the T-cell therapy approach from the lab to the clinic. GMP facilities manufacture drug-, cell- or gene-based therapies according to strict standards set by the Food and Drug Administration (FDA). The GMP facility at the Center for Childhood Cancer Research is one of only three GMPs in the nation that is owned and operated by a freestanding children's hospital. It is the only GMP facility on the West Coast dedicated to pediatric research.

Children's Center for Childhood Cancer Research grand opening was celebrated with a small event yesterday evening, where community members received tours of the new center and heard from Dr. Jensen; Children's CEO Thomas Hansen, MD; and Seattle Children's Research Institute President Jim Hendricks, PhD who discussed the center's vision to treat and cure childhood cancer. Hi-resolution photos from the event and of the center can be found here: http://www.flickr.com/photos/38997016@N03/sets/72157627194479134/

"Seattle Children's objective for the Center for Childhood Cancer Research is to provide a new standard of care for childhood cancer - one where a tube of a child's own blood is the cure. There's no surgery, no chemotherapy, no radiation and the worst side effects are having symptoms of a common cold for a few days," said Bruder Stapleton, MD, chief academic officer and senior vice president at Children's. "We are pleased to appoint Dr. Jensen as director of our Center for Childhood Cancer Research, where he'll be able to continue his work to advance the treatment of childhood cancer that has the potential to change lives all over the world."

Dr. Michael Jensen Appointed Director of Center for Childhood Cancer Research

Dr. Jensen, who has assumed the role of director for the Center for Childhood Cancer Research, joined Seattle Children's in 2010 after spending 13 years at City of Hope National Medical Center in Calif., where he developed a research program focused on cancer immunotherapy and translated this work into pioneering clinical trials. With his return to Seattle, he is able to redouble these efforts focused specifically on the most urgent needs of children battling cancer.

"The quality of medical care that kids receive at Seattle Children's Hospital, together with the depth and breadth of research at the Seattle Children's Research Institute and the scientific community here in Seattle, created a perfect situation for me to come back and apply what I've learned about treating childhood cancer," said Dr. Jensen. "Children's is committed to leading the field of cancer immunotherapy for the treatment of childhood cancers. Seattle is the right place and now is right the time to make the advances in the research laboratory a treatment reality for patients in need."